drug_type
RELEVANT_DRUG
intervention_type
Biological (CAR T-cell therapy)
drug_description
Autologous CD19-directed CAR T-cell therapy in which a patient's T cells are engineered ex vivo to express a CAR recognizing CD19 on malignant B cells, inducing T-cell effector functions and cytotoxicity in NHL/CLL.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Lisocabtagene Maraleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered ex vivo to express a CD19-specific chimeric antigen receptor; upon binding CD19 on malignant B cells, the CAR activates T-cell effector functions (cytokine release and perforin/granzyme-mediated cytotoxicity) to eliminate CD19+ cells.
drug_name
Lisocabtagene maraleucel (liso-cel)
nct_id_drug_ref
NCT06357754